Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation
- PMID: 9248850
- DOI: 10.1007/BF01747190
Changes in coagulation and fibrinolytic parameters caused by extracorporeal circulation
Abstract
During cardiopulmonary bypass (CPB) mechanical stress and the contact of blood with artificial surfaces lead to the activation of pro- and anticoagulant systems and the complement cascade, and to changes in cellular components. This phenomenon causes the "postperfusion-syndrome", with leukocytosis, increased capillary permeability, accumulation of interstitial fluid, and organ dysfunction. In this study, we focused on the influence of the extracorporeal circulation, sternotomy, and heparin administration on the activation of coagulation and fibrinolysis. In 15 patients we investigated coagulation parameters before, during and post CPB, i.e., fibrinogen, antithrombin (AT) III, thrombin-antithrombin complex (TAT), prothrombin fragments F1 + 2 (F1 + 2), factor (F) XIIa, tissue factor (TF), and parameters of the fibrinolytic system, i.e., plasmin-antiplasmin-complex (PAP), D-dimer, tissue-plasminogen-activator (tPA), urokinase-type plasminogen activator (uPA), and plasminogen-activator inhibitor type 1 (PAI 1). The results demonstrate distinct alterations in the above mentioned parameters. Despite administration of a high dose of heparin (activated clotting time [ACT] > 450s) combined with a low dose of aprotinin, activation of the coagulation and fibrinolytic pathways was observed. We found this activation was mainly caused by CPB and not by sternotomy. The activation of coagulation was due to foreign surface contact (F XII => F XIIa) as well as to an effect of tissue factor release in the late phase of CPB. The enhanced fibrinolytic activity during CPB was, at least in part, caused by tPA and was followed by PAI 1 release.
Similar articles
-
Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin?J Cardiovasc Pharmacol. 1996;27 Suppl 1:S50-7. doi: 10.1097/00005344-199600001-00011. J Cardiovasc Pharmacol. 1996. PMID: 8938284 Review.
-
Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass.Thromb Haemost. 1997 Feb;77(2):270-7. Thromb Haemost. 1997. PMID: 9157580
-
Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass.J Thorac Cardiovasc Surg. 1996 Jan;111(1):1-11; discussion 11-2. doi: 10.1016/s0022-5223(96)70395-1. J Thorac Cardiovasc Surg. 1996. PMID: 8551753 Clinical Trial.
-
Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.Ann Hematol. 1993 Jul;67(1):33-6. doi: 10.1007/BF01709663. Ann Hematol. 1993. PMID: 8392873
-
Hemostatic-endothelial interactions: a potential anticoagulant role of the endothelium in the pulmonary circulation during cardiac surgery.J Cardiothorac Vasc Anesth. 1997 May;11(3):329-36. doi: 10.1016/s1053-0770(97)90103-8. J Cardiothorac Vasc Anesth. 1997. PMID: 9161902 Review.
Cited by
-
Association between 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene with stroke or encephalopathy after cardiac surgery.Intensive Care Med. 2006 May;32(5):668-75. doi: 10.1007/s00134-006-0092-y. Epub 2006 Mar 1. Intensive Care Med. 2006. PMID: 16508752
-
Interindividual variations in cytokine levels following cardiopulmonary bypass.Heart Vessels. 1997;12(3):119-27. doi: 10.1007/BF02767129. Heart Vessels. 1997. PMID: 9496462 Clinical Trial.
-
Initial experience with recombinant antithrombin to treat antithrombin deficiency in patients on extracorporeal membrane oxygenation.J Extra Corpor Technol. 2014 Mar;46(1):84-90. J Extra Corpor Technol. 2014. PMID: 24779124 Free PMC article.
-
Reduced release of tissue factor by application of a centrifugal pump during cardiopulmonary bypass.Heart Vessels. 1998;13(3):147-51. doi: 10.1007/BF01747832. Heart Vessels. 1998. PMID: 10328185 Clinical Trial.
-
Characterization of von Willebrand factor in primary pulmonary hypertension.Heart Vessels. 1999;14(5):246-52. doi: 10.1007/BF01747854. Heart Vessels. 1999. PMID: 10830921 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous